NCT07322796 Smoking Cessation Before Bronchoscopy or CT-guided Puncture
| NCT ID | NCT07322796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RWTH Aachen University |
| Condition | Pulmonary Nodule, Solitary |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2026-01-01 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nicotine is the most common preventable cause of death and is responsible for over seven million deaths worldwide. If current trends continue, tobacco will kill more than eight million people worldwide every year by 2030. Smoking tobacco products is the most important risk factor for the development of lung cancer. Passive smoking is also a major cause of lung cancer. Since July 2024, smokers and former smokers have been able to receive a low-radiation CT scan under certain conditions to detect lung cancer at an early stage. It is therefore to be expected that the number of diagnoses of pulmonary lesions or nodules will increase in the near future. The risk of developing and dying from tobacco-related diseases is reduced once nicotine cessation begins. Screening all patients for tobacco use, e-cigarette use, and providing behavioral counseling and pharmacotherapy to quit smoking are among the most valuable preventive services we can offer in healthcare. Nicotine dependence can be estimated using the so-called Fagerström test. An additional evaluation of nicotine behavior can be carried out by testing cotinine in urine, a method that is used, for example, in the listing for lung transplantation. Cotinine is a degradation product of nicotine that can be detected in the urine of smokers and passive smokers. Cotinine levels in urine depend on the frequency and quantity of nicotine consumption. The half-life of cotinine is 16 to 22 hours, which means that half of the cotinine is excreted from the body after this time. Another marker that can be used as a measure of tobacco consumption is carboxyhaemoglobin (COHb). This is hemoglobin with carbon monoxide at the binding site for oxygen. The reference range for carboxyhaemoglobin is 0.4 - 1.6 %. In smokers, values of 3-10 % are still considered normal. In our department, the smoking status of patients is assessed upon first contact. Support options for smoking cessation are offered and, upon request, initiated. Previous studies have shown that smoking is a risk factor for complications after thoracic surgical procedures and that patients who underwent thoracic surgery quit smoking almost twice as often compared to patients who did not undergo surgery. However, to the best of our knowledge, there is currently no study regarding smoking cessation before intervention in patients with nodules needing clarification (bronchoscopy or CT-guided puncture). Therefore, the aim of the study is to support and monitor smoking cessation before intervention in patients with nodules needing further diagnosis (bronchoscopy or CT-guided puncture).
Eligibility Criteria
Inclusion Criteria: * The patient is an active smoker by the time of the initial presentation in our pneumological outpatient clinic for the clarification of a suspicious nodule Exclusion Criteria: * Current or past medically relevant illness or treatment that could affect the evaluability of the study. * Expected lack of willingness to actively participate in study-related measures.
Contact & Investigator
Michael Dreher Univ.-Prof. Dr.med
STUDY DIRECTOR
University Hospital, Aachen
Frequently Asked Questions
Who can join the NCT07322796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Nodule, Solitary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07322796 currently recruiting?
Yes, NCT07322796 is actively recruiting participants. Contact the research team at maetou@ukaachen.de for enrollment information.
Where is the NCT07322796 trial being conducted?
This trial is being conducted at Aachen, Germany.
Who is sponsoring the NCT07322796 clinical trial?
NCT07322796 is sponsored by RWTH Aachen University. The principal investigator is Michael Dreher Univ.-Prof. Dr.med at University Hospital, Aachen. The trial plans to enroll 25 participants.